Preferred Label : Cemacabtagene Ansegedleucel;
NCIt synonyms : Allogeneic Anti-CD19 CAR-T Cells ALLO-501A; Allogeneic CD19-specific CAR T-cells ALLO-501A; Allogeneic Anti-CD19 CAR T-lymphocytes ALLO-501A; Allogeneic Anti-CD19 CAR T-cells ALLO-501A;
NCIt definition : A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like
effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric
antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential
immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell
receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon
administration, cemacabtagene ansegedleucel specifically targets and binds to CD19-expressing
tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen
is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52
monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout
of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential
induction of graft-versus-host disease (GvHD) by the donor T-cells.;
UNII : W3X22HS7XD;
Molecule name : ALLO-501A; ALLO 501A;
NCI Metathesaurus CUI : CL1406567;
Origin ID : C172708;
UMLS CUI : C5908087;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
